Nox Medical strives to advance sleep medicine by actively supporting sleep research and the scientific community. For years, we have organized and sponsored symposiums with high scientific value at key events. At this year’s SLEEP Meeting, Nox Medical will sponsor a satellite symposium and invite four leading sleep researchers and physicians to speak on the topic of the Future of Sleep Diagnostics and Ambulatory PSG. Titled, The emergence of ambulatory PSG Type II sleep testing, the symposium will cover the state of ambulatory PSG Type II testing in sleep medicine. Discussions will address the latest trends in ambulatory PSG research, learnings from Type II sleep studies in a clinical setting, and what they can mean for the industry’s future. Technology advancements are emerging with digital tools and telehealth solutions that can help scale sleep health care to diagnose and treat large patient populations. Providers have already begun to shift from in-hospital to home based sleep tests. Furthermore, artificial intelligence has shown tremendous potential to improve diagnostic accuracy, increase efficiency and provide cost-effective home sleep testing for patients suspected of sleep-disordered breathing.
The Emergence of Ambulatory PSG Type II
Recent growth in sleep health awareness has caused the demand for sleep studies to rise. To meet this increased demand, the field of sleep diagnostics has increasingly turned to at-home sleep studies. While in-laboratory polysomnography (PSG) sleep studies remain the Gold Standard, ambulatory Type II PSG sleep studies are emerging as a diagnostic tool and are already an accepted technique. Ambulatory PSG collects a comprehensive overnight polysomnography study in the comfort of a patient’s home, gathering all the necessary data to be considered a proper sleep diagnostic study. In comparison, Type III studies generally refer to home apnea sleep testing. Clinical investigators have demonstrated that ambulatory Type II sleep studies are feasible and reliable compared with in-lab studies¹²³. The flexibility of wireless and portable PSG systems allows sleep clinics to attend to more patients by transitioning studies from the laboratory to the home.
Nox Satellite Symposium
Tuesday, June 7 at 6:15 pm
Westin Charlotte Hotel
This event is for everyone interested in advancing sleep diagnostics and how we can continue to evolve sleep medicine. The discussions will be made available by four excellent speakers. We will be serving drinks and light fare at the start of the event.
Dennis Hwang, MD
Diagnostic Paradigms in Evolution: Will Sleep Medicine Be Recogizable in 10 years?
New technologies, integration of the health information technology ecosystem, and emergence of artificial intelligence can address limitations with current sleep diagnostic approaches, advance personalized care, and support shifts in emphasis towards care management and directly targeting clinical outcomes. This session will discuss potential paradigm shifts in sleep medicine and describe a how the specialty could look very different.
Dennis Hwang, MD
Dennis Hwang a sleep and pulmonary physician, the medical director at the Kaiser Permanente San Bernardino County Sleep Disorders Center, and co-chair of sleep medicine for the Southern California Permanente Medical Group. He was the chair of the EHR Integration Task force and a member of various technology and artificial intelligence committees with the AASM. His research interest is in innovating mechanisms of integrating healthcare-related technologies to create “big data” sets that can enable development of machine learning approaches to innovate novel diagnostic approaches and care management tools to support population management and personalized medicine strategies.
Christopher Cielo, MD, Ignacio Tapia, MD
Type II home sleep testing in children: past, present, and future
In-laboratory polysomnography is the Gold Standard for the diagnosis of pediatric OSA, and the only AASM-recommended pediatric sleep apnea testing. However, in-lab PSG has its limitations with insufficient availability, high cost, and duress for patients and families. In their talk, Dr. Cielo and Dr. Tapia will share their research findings on Type II testing in children. They will discuss the rationale for Type II testing in children versus more limited polygraph, and how ambulatory PSG Type II performs in comparison to in-lab PSG Type, I testing.
Christopher Cielo, MD
Christopher Cielo is a pediatric pulmonologist and sleep medicine physician with a background in clinical and translational research focused on the evaluation, mechanisms and management of obstructive sleep apnea (OSA) in children, with a particular focus on infant populations and high-risk children including those with craniofacial conditions and Down syndrome. He spent four years completing dual fellowships in sleep medicine and pediatric pulmonology at Children’s Hospital of Philadelphia (CHOP) and completed a Master’s of Science in Translational Research at the University of Pennsylvania. His K23 project has used sophisticated imaging techniques and growth assessments to better understand the mechanisms and effects of OSA in infants with micrognathia and he is co-investigator on a number of ongoing NIH-funded studies related to OSA in children. In addition to his own research, he directs the Sleep Core for CHOP’s Center for Human Phenomic Science, which ensures high-quality research sleep testing for investigators at CHOP.
Ignacio Tapia, MD
Dr. Tapia is an attending physician in the Sleep Center/Pulmonary Division of the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is also the pediatric pulmonology fellowship program director. He graduated from the University of Concepcion, Chile and completed his pediatric residency and pediatric pulmonology fellowship at CHOP. He is board certified in General Pediatrics, Pediatric Pulmonology and Sleep Medicine. His main research interests are the pathophysiology of the Obstructive Sleep Apnea Syndrome (OSAS) in children, and the consequences of OSAS in individuals with Down syndrome. His research has been funded by the American Heart Association, the University of Pennsylvania, the American Sleep Medicine Foundation, and the National Institutes of Health.
Chair: Parina Aggarwal, MD
Dr. Aggarwal is a practicing sleep medicine physician for Fusion Sleep in Atlanta, Georgia and sees both adult and pediatric populations. She completed her Bachelor’s degree in Electrical Engineering from Georgia Tech and subsequently attended Emory University School of Medicine. She completed her residency in Internal Medicine and fellowship in Sleep Medicine at the Hospital of the University of Pennsylvania. Due to her background in both medicine and engineering, she was recruited and served as Medical Director of NoxHealth’s SleepCharge program, developing technology based sleep telehealth protocols for employee based wellness programs for 3 years. She currently sees adults and pediatric patients at FusionSleep and works with Nox developers in providing software feedback. She is also pursuing certification in lifestyle medicine as she sees sleep as the first step in lifestyle change to prevent and reverse chronic disease.
The symposium will take place on Wednesday, June 7th, at the Westin Charlotte Hotel. Please register for the event HERE
Photo from Nox Symposium at World Sleep 2022
¹ Yoon, Dae Wui, et al. “Evaluation of the feasibility and preference of Nox-A1 type 2 ambulatory device for unattended home sleep test: a randomized crossover study.” Sleep and Biological Rhythms 17.3 (2019): 297-304.
² Ioan I, Weick D, Schweitzer C, Guyon A, Coutier L, Franco P. Feasibility of Parent-Attended Ambulatory Polysomnography in Children With Suspected Obstructive Sleep Apnea. J Clin Sleep Med. February 2020. doi:10.5664/jcsm.8372
³ Russo K, Greenhill J, Burgess S. Home (Level 2) polysomnography is feasible in children with suspected sleep disorders. Sleep Med. 2021;88:157-161. doi:10.1016/j.sleep.2021.10.024